← Back to patent-cliff list
donepezil (Vyant Bio)
Tier C — Watch / tradedonepezil (Vyant Bio)
Vyant Bio Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：AChE
Indications (approved)：Rett syndrome
Regional status
US
-
2021-12-01
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of donepezil (Vyant Bio)?
Approved indications include: Rett syndrome.
When does the donepezil (Vyant Bio) patent expire?
No public expiry year is available for donepezil (Vyant Bio) yet; this page updates once verified.
How do I get a quote for donepezil (Vyant Bio) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-03